menu
    • menu

    Company profile for Coya Therapeutics

    NEW Drugs in Dev: 8
    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    The company’s proprietary CTreg™ (cryopreservation for Tregs) system is the first in the industry to create an ‘off the shelf’ approach to Treg cell therapy allowing for serial infusions. Through our patented TAI™ (Tregs Against Inflammation) and EAI™ (Exosomes Against Inflammation) platforms , Coya is focused on the advancement of disease modifying approaches to address the significant unmet medical needs of patie...
    The company’s proprietary CTreg™ (cryopreservation for Tregs) system is the first in the industry to create an ‘off the shelf’ approach to Treg cell therapy allowing for serial infusions. Through our patented TAI™ (Tregs Against Inflammation) and EAI™ (Exosomes Against Inflammation) platforms , Coya is focused on the advancement of disease modifying approaches to address the significant unmet medical needs of patients with ALS, Parkinson’s, Alzheimer’s, FTD and autoimmune diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Coya TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    5850 San Felipe St, Suite 500, Houston, Texas 77057
    Telephone
    Telephone
    1 (800) 587-8170
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.coyatherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/coya-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/CoyaTx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Coya's ALSTARS Trial Begins Blinded Active-Treatment Phase
    Coya's ALSTARS Trial Begins Blinded Active-Treatment Phase

    08 Jun 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260608610243/en/Coya-Therapeutics-Announces-the-First-Cohort-of-Patients-in-the-ALSTARS-Trial-Have-Begun-the-Blinded-Active-Treatment-Extension-Phase

    BUSINESSWIRE
    08 Jun 2026
    Share Share
    Coya Therapeutics to Present ALSTARS Trial Design at Summit
    Coya Therapeutics to Present ALSTARS Trial Design at Summit

    27 May 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260527446509/en/Coya-Therapeutics-to-Present-ALSTARS-Trial-Design-at-the-5th-ALS-Drug-Development-Summit

    BUSINESSWIRE
    27 May 2026
    Share Share
    FDA Grants Coya Therapeutics Fast Track for COYA 302 in ALS
    FDA Grants Coya Therapeutics Fast Track for COYA 302 in ALS

    12 May 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260512522130/en/Coya-Therapeutics-Has-Been-Granted-U.S.-FDA-Fast-Track-Designation-for-COYA-302-for-the-Treatment-of-Amyotrophic-Lateral-Sclerosis-ALS

    BUSINESSWIRE
    12 May 2026
    Share Share
    Coya Therapeutics Reports Q1 2026 Results and Corporate Update
    Coya Therapeutics Reports Q1 2026 Results and Corporate Update

    12 May 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260512279103/en/Coya-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Provides-a-Corporate-Update

    BUSINESSWIRE
    12 May 2026
    Share Share
    Coya Publishes Longitudinal COYA 302 ALS Data: Outcomes &
    Coya Publishes Longitudinal COYA 302 ALS Data: Outcomes &

    09 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-09/coya-therapeutics-announces-publication-demonstrating-correlation-between-longitudinal-biomarker-dat

    PHARMIWEB
    09 Apr 2026
    Share Share
    Coya Therapeutics Appoints Mark H. Pavao as Independent Director
    Coya Therapeutics Appoints Mark H. Pavao as Independent Director

    02 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-02/coya-therapeutics-announces-planned-board-transition-and-appointment-of-mark-h-pavao-as-independent

    PHARMIWEB
    02 Apr 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search